
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
Keywords: cancer immunotherapy; CPG oligodeoxynucleotides; cutaneous T-cell lymphoma; immunotherapy; PF-3512676; Toll-like receptor 9AE, adverse event; CAILS, Composite Assessment of Index Lesion Severity; CR, complete response; CTCL, cutaneous T-cell lymphoma; DC,